European Funds for Regional Development

Note: The project descriptions reflect the status and objectives of the projects at their initial stage.

North Rhine-Westphalia

OVARSENSE

Development of an ultrasensitive, non-invasive method for the early detection and determination of minimal residual disease in ovarian cancer using circulating tumor DNA in liquid biopsies

Project duration: January 2026 – ongoing

Project goal: A test that can both determine minimal residual disease, as well as being used for the early detection of ovarian cancer is under development. This minimally invasive method reduces the burden on patients and offers significantly higher accuracy than traditional methods.

Approach: The goal is to enable precise and personalized diagnostics through the analysis of circulating tumor DNA (ctDNA) using liquid biopsies and next-generation sequencing (NGS). This innovative technology allows for the early detection of recurrences and supports personalized therapy decisions.

Identifier: IN-GE-3-020c

Project coordinator

CountryCityInstitution
DECologneLiqomics GmbH

Project partner(s)

CountryCityInstitution
DEBergisch GladbachGynäkologisches Krebszentrum, Evangelisches Krankenhaus Bergisch Gladbach gGmbH
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

SARS Diagnostics

SARS-CoV-2-specific T cell diagnostics for monitoring long-term immunity as chance in the corona crisis

Project duration: July 2020 – October 2022

Project goal: The goal of the project was to develop a new cell-based assay that provides more reliable information on the epidemiological distribution of COVID-19 and the immune status of the population. By using a robotic high-throughput system for broad population screening, a system was developed for rapid and reproducible automated processing of blood samples at high-throughput speed.

Approach: Miltenyi Biotec aimed to develop a new, more informative rapid test based on the cellular immune response that determines the virus-specific T cells in the blood responsible for killing virus-infected cells. In combination with serological testing, this new cell-based test provides a concrete indication of who in the population is acutely infected, has already contracted COVID-19, or has not been in contact with the virus.

Identifier: MIL-1-1

Project coordinator

CountryCityInstitution
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

Project partner(s)

CountryCityInstitution
DEMönchengladbachMVZ Dr. Stein + Kollegen GbR
DEAachenUniklinik RWTH Aachen
DEBonnUniversitätsklinikum Bonn, Institut für Virologie
DEAachenLabor Dr. Wisplinghoff

SARS Therapy

Therapeutic approach with SARS-CoV-2-specific T cells for the treatment of severely ill COVID-19 patients

Project duration: July 2020 – December 2022

Project goal: When the SARS-CoV-2 pandemic hit the world in 2019 – 2020, an effective treatment against this novel and devastating viral threat was urgently needed. Prior to the pandemic, Miltenyi Biotec had developed an automated process to isolate virus-specific T cells from donor material in a GMP environment for adoptive cellular transfer into patients of need (e.g., after stem cell transplantation). During the SARS therapy project, Miltenyi Biotec, together with partner University Clinics Cologne, developed a novel therapeutic concept in which SARS-CoV-2-specific T cells were isolated from human leukocyte antigen (HLA)-matched convalescent donors and then transferred into severely ill COVID-19 patients. To be prepared for future pandemics, the project additionally set up a network of competence centers to manufacture virus-specific T cells for adoptive transfer.

Approach: SARS-CoV-2-specific T cells from COVID-19 convalescent donors with suitable HLAs were enriched and isolated with Miltenyi Biotec’s proprietary Cytokine Capture System on the CliniMACS Prodigy® instrument. To generate these T cells with the Cytokine Capture System, SARS-CoV-2-specific peptide pools were developed and produced in MACS GMP quality.

In addition to being provided with the required devices to manufacture and control the quality of virus-specific T cells, seven centers in the German federal state North Rhine-Westphalia were trained in their use, making these centers well-equipped to rapidly produce virus-specific T cells to be prepared for future pandemics.

Identifier: MIL-1-2-A

Project coordinator

CountryCityInstitution
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

Project partner(s)

CountryCityInstitution
DECologneUniklinik Köln, Klinik I für Innere Medizin

CardioPatch

Vascularized, bioartificial heart muscle from induced pluripotent stem cells

Project duration: December 2019 – November 2022

Project goal: According to the World Health Organization, cardiovascular diseases are the leading causes of death globally. A key technology for treating these diseases in the future involves manufacturing bioartificial tissue. However, a major technological obstacle is the lack of functional blood vessel structures in larger tissues. CardioPatch addressed this problem through an ambitious, transdisciplinary approach with the overall goal of in vitro production of vascularized heart muscle tissue.

Approach: The CardioPatch consortium joined together experts from a variety of scientific disciplines. The aim was to solve the problem of missing vascularization in bioartificial heart tissue through a combined bottom-up/top-down process. Within this process, blood vessels were inscribed within photochemically functionalized, biocompatible polymers. These polymers were subsequently colonized with various cell types obtained from human induced pluripotent stem cells (iPSCs) to generate bioartificial heart tissue.

More information: www.leitmarktagentur.nrw

Identifier: EFRE-0801786; LS-2-2-029f

Project coordinator

CountryCityInstitution
DECologneUniversitätsklinikum Köln, Klinik und Poliklinik für Kinderkardiologie

Project partner(s)

CountryCityInstitution
DEAachenFraunhofer-Institut für Lasertechnik (ILT)
DEAachenLightFab GmbH (LIGHTFAB)
DEDortmundTaros Chemicals GmbH und Co. KG (TAROS)
DECologneUniversität zu Köln (UNIK)
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

TraCAR

Non-invasive imaging of pharmacokinetics and optimization of CAR T cell therapies of solid tumors

Project duration: December 2019 – November 2022

Project goal: CAR T cell therapies are a promising option for treatment of leukemia. But if the CAR T cells also target healthy cells, these therapies can have undesired side effects. Until now, they have also been less effective against solid tumors, possibly due to the immunosuppressive microenvironment of these tumors. To further optimize CAR T cell therapies, it is necessary to gain a fundamental understanding of the distribution and specific activity of CAR T cells after their injection into the organism. TraCAR met this challenge by using a noninvasive imaging technique such as PET/SPECT to observe optimized CAR T cells in a mouse tumor model.

Approach: In this pre-clinical study, CAR T cells were optimized based on immunomodulation and epitope masking strategies to improve their therapeutic efficacy. To be able to analyze their distribution within the mouse model, the CAR T cells were labeled with radioactive tracers and/or expressed a reporter gene. In vivo experiments were used to evaluate a nuclear medical-based imaging strategy. Finally, this imaging strategy was used to assess the efficacy of the optimized CAR T cells in vivo.

More information: www.leitmarktagentur.nrw

Identifier: EFRE_0801760; LS-2-2-050a

Project coordinator

CountryCityInstitution
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

Project partner(s)

CountryCityInstitution
DEMünsterWestfälische Wilhelms-Universität-Münster

iCAN33

Project duration: November 2018 – October 2021

Project goal: Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is characterized by uncontrolled growth of abnormal cells. With current therapies, only 30% of adults and 70% of children can be cured. Therefore, the iCAN33 consortium aimed to increase the chances of recovery by developing an immunotherapy for AML that uses allogeneic CAR NK cells. The project generated the basics, protocols, and preclinical data to be used for subsequent clinical studies.

Approach: The iCAN33 consortium brought together experts from the fields of NK cell function, CAR-technology, and clinical cell therapeutics. Their work included isolating NK cells from the blood of healthy patients to use in generating CAR NK cells that recognized a specific tumor antigen on the AML blasts. Throughout this project, all regulatory hurdles were considered to pave the way for a CAR NK cell therapy for AML patients.

More information: www.leitmarktagentur.nrw

Identifier: EFRE-0801288

Project coordinator

CountryCityInstitution
DEEssenUniversitätsklinikum Essen, Klinik für Kinderheilkunde III

Project partner(s)

CountryCityInstitution
DEEssenUniversitätsklinikum Essen, Klinik für Hämatologie
DEEssenUniversitätsklinikum Essen, Klinik für Knochenmarktransplantation
DEEssenUniversitätsklinikum Essen, Institut für Transfusionsmedizin
DEDüsseldorfUniversitätsklinikum Düsseldorf, Institut für Transplantationsdiagnostik und Zelltherapeutika
DEBonnUniversitätsklinikum Bonn, Medizinische Klinik III für Onkologie, Hämatologie, Immunonkologie und Rheumatologie
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

ImmunePredict

Development of new predictive markers for response to immune checkpoint inhibitors of solid tumors

Project duration: November 2018 – January 2022

Project goal: Personalized cancer therapies are based on the concept that cancer is an enormously heterogeneous disease and patients can be optimally treated with therapies based on the tumor’s specific genetic and cellular information. In this context, modern cancer therapy is subject to constant progress. In recent years this progress has included the development of drugs (immune checkpoint inhibitors) that activate the body's own defense mechanisms, allowing cancer cells to be attacked and killed. This form of immunotherapy has led to a dramatic improvement in the prognosis of some patients. Unfortunately, the current options for reliably predicting which patients will benefit from which therapies are very limited. To address this gap, the lmmunePredict research consortium used novel imaging technologies to collect a variety of cellular information and create a comprehensive molecular characterization of the tumors.

Approach: A response to immunotherapy is dependent on the immune system successfully recognizing and destroying the tumor. To quantify the multiple factors and factor interactions necessary for the immune system to successfully do this, MICS-based staining and biomedical image analysis were combined. The qualitative and quantitative measurement of immune effector molecules up to immune effector cells was carried out to develop a diagnostic assay that comprehensively extends the principle of personalized medicine to any therapy, including immunotherapies, and allows patients to be accurately selected for the most effective therapy.

More information: www.leitmarktagentur.nrw

Identifier: EFRE-0801304

Project coordinator

CountryCityInstitution
DECologneUniversity of Cologne

Project partner(s)

CountryCityInstitution
DEHammUniversity of Applied Sciences Hamm-Lippstadt
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

Mecklenburg-Western Pomerania

NEXCELL

Next-Generation Point-of-Care Cell & Gene Therapy Platform

Project duration: February 2025 – ongoing

Project goal: The aim of this joint project is to develop a highly automated and fully digitalized next-generation cell and gene therapy platform. The NEXCELL platform aims to integrate technological innovations to enable standardized clinical manufacturing processes with the highest product quality, automated analytics, AI-optimized data management, and maximum practicality. A particular focus will be placed on facilitating easier access to personalized cell products through “point-of-care” manufacturing directly at the site of treatment.

Approach: First, new biomarkers and target structures will be identified and characterized from human samples based on the indications of acute myeloid leukemia (AML), glioblastoma, and head and neck squamous cell carcinoma (HNSCC). Using spatial imaging techniques to analyze tumor microenvironments and neoantigens, a multi-omic profiling approach will be implemented. Furthermore, the research will focus on synthetic peptide pools for T-cell stimulation based on the identified neoantigen structures.
The second objective is to develop a highly automated device that combines novel analytical technologies with digital process management. This includes designing and prototyping the NEXCELL instrument, integrating advanced sensor and cytometric functions, creating a new filling unit, and implementing centralized software for process control, monitoring, and documentation. Additionally, the project will promote the integration of innovative disposables and reagents.

Identifier: TBI-1-140-U-043

Project coordinator

CountryCityInstitution
DETeterowMiltenyi Biotec B.V. & Co.KG

Project partner(s)

CountryCityInstitution
DERostockUniversitätsmedizin Rostock, ZIM III
DERostockUniversität Rostock, Institute for visual and analytic computing
DEParchimRoweMed-Medical 4 life

PiCoP

Peptide-based immunization strategies for colon and pancreas tumors

Project duration: June 2017 – June 2023

Project goal: The aim of this joint project was to develop a workflow for identifying immune-relevant tumor mutations and using these identified neoantigens to create patient-specific immunization strategies. Relevant indications in this project were colon and pancreatic cancer. The goal was the creation of industrial competence to support innovative tumor vaccination therapies.

Approach: In the first phase of the project, patients with metastatic colon cancer and patients with pancreatic cancer were recruited. The samples taken were analyzed with a somatic cancer panel and underwent whole genome sequencing. Somatic mutations were evaluated, and Miltenyi Biotec’s tumor cell enrichment technology was used. In addition, serum samples were obtained monthly to analyze and track driver mutations in cell-free DNA.

Tumor sequencing, prediction, and validation of protein-coding somatic mutations were performed and evaluated using variant lists, and an HLA-matched epitope mix was selected and prepared for individual patients under GMP/GLP conditions. The administration of the vaccinations within the framework of a clinical study / therapeutic trial was then carried out in the recruiting centers of the university hospitals of Rostock and Greifswald.

Identifier: TBI-V-a-234-VBU-085

Project coordinator

CountryCityInstitution
DEBergisch GladbachMiltenyi Biotec B.V. & Co. KG

Project partner(s)

CountryCityInstitution
DERostockCentogene
DEGreifswaldUniversitätsmedizin Greifswald
DERostockUniversitätsmedizin Rostock

Partner with us

Are you looking for a reliable partner for your next grant project?

Get in touch with our Grant Management Team to discuss your ideas.